BioCentury | Jul 8, 2019
Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BioCentury | Feb 2, 2018
Finance

Private ambition

BB Biotech AG (SIX:BION; Xetra:BBZA) made a rare private investment in Moderna Therapeutics Inc.’s $500 million series G round and wants to see clinical proof-of-concept data from at least one rare liver disease asset before...
BioCentury | Nov 3, 2017
Clinical News

Probiodrug planning Phase IIb trials of PQ912 for early AD

Next year, Probiodrug AG (Euronext:PBD) plans to start a European Phase IIb trial of glutaminyl cyclase (QC) inhibitor PQ912 to treat early Alzheimer’s disease. The trial will evaluate safety and efficacy of the optimal dose...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro , cell culture and mouse studies identified a diphenyl-imidazole-based QC inhibitor that could help treat AD. Chemical synthesis and in vitro testing of diphenyl-imidazole analogs yielded a compound that inhibited...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in...
BioCentury | Jun 16, 2017
Clinical News

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

Probiodrug AG (Euronext:PBD) reported data from the Phase IIa SAPHIR trial in 120 patients with early Alzheimer's disease (AD) showing that there was no significant difference between patients who received twice-daily 800 mg oral PQ912...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
BioCentury | Oct 10, 2016
Financial News

Probiodrug completes private placement

Probiodrug AG (Euronext:PBD), Halle/Saale, Germany Business: Neurology Date completed: 2016-10-06 Type: Private placement Raised: EUR14.9 million ($16.7 million) Shares: 744,248 Price: EUR20 Shares after offering: 8.2 million Investor: Institutional investors Underwriters: Kempen & Co.; Bank...
BioCentury | Aug 15, 2016
Company News

Management tracks

Antibody and cell therapy company Sorrento Therapeutics Inc. (NASDAQ:SNRE) hired Jerome Zeldis as CMO and president of clinical development. Zeldis was CMO of Celgene Corp. (NASDAQ:CELG) and CEO of its Celgene Global Health unit. Rare...
Items per page:
1 - 10 of 75
BioCentury | Jul 8, 2019
Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BioCentury | Feb 2, 2018
Finance

Private ambition

BB Biotech AG (SIX:BION; Xetra:BBZA) made a rare private investment in Moderna Therapeutics Inc.’s $500 million series G round and wants to see clinical proof-of-concept data from at least one rare liver disease asset before...
BioCentury | Nov 3, 2017
Clinical News

Probiodrug planning Phase IIb trials of PQ912 for early AD

Next year, Probiodrug AG (Euronext:PBD) plans to start a European Phase IIb trial of glutaminyl cyclase (QC) inhibitor PQ912 to treat early Alzheimer’s disease. The trial will evaluate safety and efficacy of the optimal dose...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro , cell culture and mouse studies identified a diphenyl-imidazole-based QC inhibitor that could help treat AD. Chemical synthesis and in vitro testing of diphenyl-imidazole analogs yielded a compound that inhibited...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in...
BioCentury | Jun 16, 2017
Clinical News

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

Probiodrug AG (Euronext:PBD) reported data from the Phase IIa SAPHIR trial in 120 patients with early Alzheimer's disease (AD) showing that there was no significant difference between patients who received twice-daily 800 mg oral PQ912...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
BioCentury | Oct 10, 2016
Financial News

Probiodrug completes private placement

Probiodrug AG (Euronext:PBD), Halle/Saale, Germany Business: Neurology Date completed: 2016-10-06 Type: Private placement Raised: EUR14.9 million ($16.7 million) Shares: 744,248 Price: EUR20 Shares after offering: 8.2 million Investor: Institutional investors Underwriters: Kempen & Co.; Bank...
BioCentury | Aug 15, 2016
Company News

Management tracks

Antibody and cell therapy company Sorrento Therapeutics Inc. (NASDAQ:SNRE) hired Jerome Zeldis as CMO and president of clinical development. Zeldis was CMO of Celgene Corp. (NASDAQ:CELG) and CEO of its Celgene Global Health unit. Rare...
Items per page:
1 - 10 of 75